NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Warrants issued and outstanding (Details)	6 Months Ended
	Mar. 31, 2022 $ / shares shares
Warrants [Roll Forward]
Warrants, Outstanding at the beginning of the period \| shares	895,939
Warrants, Expired \| shares	(20,627)
Warrants, Outstanding at the end of the period \| shares	875,312
Warrants, Exercisable at the end of the period \| shares	875,312
Weighted average exercise price, Outstanding at the beginning of the period \| $ / shares	$ 18.35
Weighted average exercise price, Expired \| $ / shares	55.00
Weighted average exercise price, Outstanding at the end of the period \| $ / shares	17.49
Weighted average exercise price, Exercisable at the end of the period \| $ / shares	$ 17.49
Weighted average remaining contractual term, Outstanding at the end of the period	4 months 24 days
Weighted average remaining contractual term, Exercisable at the end of the period	4 months 24 days
April 10, 2022
Warrants [Roll Forward]
Exercise price of warrants (in dollars per share) \| $ / shares	$ 20.00
Warrants, Outstanding at the end of the period \| shares	695,312
July 6, 2023
Warrants [Roll Forward]
Exercise price of warrants (in dollars per share) \| $ / shares	$ 8.73
Warrants, Outstanding at the end of the period \| shares	105,000
September 20, 2024
Warrants [Roll Forward]
Exercise price of warrants (in dollars per share) \| $ / shares	$ 6.50
Warrants, Outstanding at the end of the period \| shares	75,000